240 related articles for article (PubMed ID: 30385468)
1. Shape Features of the Lesion Habitat to Differentiate Brain Tumor Progression from Pseudoprogression on Routine Multiparametric MRI: A Multisite Study.
Ismail M; Hill V; Statsevych V; Huang R; Prasanna P; Correa R; Singh G; Bera K; Beig N; Thawani R; Madabhushi A; Aahluwalia M; Tiwari P
AJNR Am J Neuroradiol; 2018 Dec; 39(12):2187-2193. PubMed ID: 30385468
[TBL] [Abstract][Full Text] [Related]
2. Computer-Extracted Texture Features to Distinguish Cerebral Radionecrosis from Recurrent Brain Tumors on Multiparametric MRI: A Feasibility Study.
Tiwari P; Prasanna P; Wolansky L; Pinho M; Cohen M; Nayate AP; Gupta A; Singh G; Hatanpaa KJ; Sloan A; Rogers L; Madabhushi A
AJNR Am J Neuroradiol; 2016 Dec; 37(12):2231-2236. PubMed ID: 27633806
[TBL] [Abstract][Full Text] [Related]
3. Machine learning-based radiomic evaluation of treatment response prediction in glioblastoma.
Patel M; Zhan J; Natarajan K; Flintham R; Davies N; Sanghera P; Grist J; Duddalwar V; Peet A; Sawlani V
Clin Radiol; 2021 Aug; 76(8):628.e17-628.e27. PubMed ID: 33941364
[TBL] [Abstract][Full Text] [Related]
4. Imaging Glioblastoma Posttreatment: Progression, Pseudoprogression, Pseudoresponse, Radiation Necrosis.
Strauss SB; Meng A; Ebani EJ; Chiang GC
Radiol Clin North Am; 2019 Nov; 57(6):1199-1216. PubMed ID: 31582045
[TBL] [Abstract][Full Text] [Related]
5. Differentiation of Pseudoprogression from True Progressionin Glioblastoma Patients after Standard Treatment: A Machine Learning Strategy Combinedwith Radiomics Features from T
Sun YZ; Yan LF; Han Y; Nan HY; Xiao G; Tian Q; Pu WH; Li ZY; Wei XC; Wang W; Cui GB
BMC Med Imaging; 2021 Feb; 21(1):17. PubMed ID: 33535988
[TBL] [Abstract][Full Text] [Related]
6. Combination of IVIM-DWI and 3D-ASL for differentiating true progression from pseudoprogression of Glioblastoma multiforme after concurrent chemoradiotherapy: study protocol of a prospective diagnostic trial.
Liu ZC; Yan LF; Hu YC; Sun YZ; Tian Q; Nan HY; Yu Y; Sun Q; Wang W; Cui GB
BMC Med Imaging; 2017 Feb; 17(1):10. PubMed ID: 28143434
[TBL] [Abstract][Full Text] [Related]
7. Pseudoprogression in patients with glioblastoma: added value of arterial spin labeling to dynamic susceptibility contrast perfusion MR imaging.
Choi YJ; Kim HS; Jahng GH; Kim SJ; Suh DC
Acta Radiol; 2013 May; 54(4):448-54. PubMed ID: 23592805
[TBL] [Abstract][Full Text] [Related]
8. Stable and Discriminatory Radiomic Features from the Tumor and Its Habitat Associated with Progression-Free Survival in Glioblastoma: A Multi-Institutional Study.
Verma R; Hill VB; Statsevych V; Bera K; Correa R; Leo P; Ahluwalia M; Madabhushi A; Tiwari P
AJNR Am J Neuroradiol; 2022 Aug; 43(8):1115-1123. PubMed ID: 36920774
[TBL] [Abstract][Full Text] [Related]
9. Support vector machine multiparametric MRI identification of pseudoprogression from tumor recurrence in patients with resected glioblastoma.
Hu X; Wong KK; Young GS; Guo L; Wong ST
J Magn Reson Imaging; 2011 Feb; 33(2):296-305. PubMed ID: 21274970
[TBL] [Abstract][Full Text] [Related]
10. Combined iron oxide nanoparticle ferumoxytol and gadolinium contrast enhanced MRI define glioblastoma pseudoprogression.
Barajas RF; Hamilton BE; Schwartz D; McConnell HL; Pettersson DR; Horvath A; Szidonya L; Varallyay CG; Firkins J; Jaboin JJ; Kubicky CD; Raslan AM; Dogan A; Cetas JS; Ciporen J; Han SJ; Ambady P; Muldoon LL; Woltjer R; Rooney WD; Neuwelt EA
Neuro Oncol; 2019 Mar; 21(4):517-526. PubMed ID: 30277536
[TBL] [Abstract][Full Text] [Related]
11. Post-gadolinium 3-dimensional spatial, surface, and structural characteristics of glioblastomas differentiate pseudoprogression from true tumor progression.
Hansen MR; Pan E; Wilson A; McCreary M; Wang Y; Stanley T; Pinho MC; Guo X; Okuda DT
J Neurooncol; 2018 Sep; 139(3):731-738. PubMed ID: 29882044
[TBL] [Abstract][Full Text] [Related]
12. Disorder in Pixel-Level Edge Directions on T1WI Is Associated with the Degree of Radiation Necrosis in Primary and Metastatic Brain Tumors: Preliminary Findings.
Prasanna P; Rogers L; Lam TC; Cohen M; Siddalingappa A; Wolansky L; Pinho M; Gupta A; Hatanpaa KJ; Madabhushi A; Tiwari P
AJNR Am J Neuroradiol; 2019 Mar; 40(3):412-417. PubMed ID: 30733252
[TBL] [Abstract][Full Text] [Related]
13. Imaging Glioblastoma Posttreatment: Progression, Pseudoprogression, Pseudoresponse, Radiation Necrosis.
Strauss SB; Meng A; Ebani EJ; Chiang GC
Neuroimaging Clin N Am; 2021 Feb; 31(1):103-120. PubMed ID: 33220823
[TBL] [Abstract][Full Text] [Related]
14. Radiomics features to distinguish glioblastoma from primary central nervous system lymphoma on multi-parametric MRI.
Kim Y; Cho HH; Kim ST; Park H; Nam D; Kong DS
Neuroradiology; 2018 Dec; 60(12):1297-1305. PubMed ID: 30232517
[TBL] [Abstract][Full Text] [Related]
15. Role of FDG-PET/MRI, FDG-PET/CT, and Dynamic Susceptibility Contrast Perfusion MRI in Differentiating Radiation Necrosis from Tumor Recurrence in Glioblastomas.
Hojjati M; Badve C; Garg V; Tatsuoka C; Rogers L; Sloan A; Faulhaber P; Ros PR; Wolansky LJ
J Neuroimaging; 2018 Jan; 28(1):118-125. PubMed ID: 28718993
[TBL] [Abstract][Full Text] [Related]
16. Dynamic contrast enhanced T1 MRI perfusion differentiates pseudoprogression from recurrent glioblastoma.
Thomas AA; Arevalo-Perez J; Kaley T; Lyo J; Peck KK; Shi W; Zhang Z; Young RJ
J Neurooncol; 2015 Oct; 125(1):183-90. PubMed ID: 26275367
[TBL] [Abstract][Full Text] [Related]
17. The value of
Garcia JR; Cozar M; Baquero M; Fernández Barrionuevo JM; Jaramillo A; Rubio J; Maida G; Soler M; Riera E
Rev Esp Med Nucl Imagen Mol; 2017; 36(2):85-90. PubMed ID: 27503425
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma.
Wick W; Chinot OL; Bendszus M; Mason W; Henriksson R; Saran F; Nishikawa R; Revil C; Kerloeguen Y; Cloughesy T
Neuro Oncol; 2016 Oct; 18(10):1434-41. PubMed ID: 27515827
[TBL] [Abstract][Full Text] [Related]
19. Stratification of pseudoprogression and true progression of glioblastoma multiform based on longitudinal diffusion tensor imaging without segmentation.
Qian X; Tan H; Zhang J; Zhao W; Chan MD; Zhou X
Med Phys; 2016 Nov; 43(11):5889. PubMed ID: 27806598
[TBL] [Abstract][Full Text] [Related]
20. Differentiation of true-progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide by GLCM texture analysis of conventional MRI.
Chen X; Wei X; Zhang Z; Yang R; Zhu Y; Jiang X
Clin Imaging; 2015; 39(5):775-80. PubMed ID: 25956436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
